{"id":"NCT03325881","sponsor":"Shire","briefTitle":"Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years","officialTitle":"A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-09","primaryCompletion":"2018-06-07","completion":"2018-06-07","firstPosted":"2017-10-30","resultsPosted":"2019-08-13","lastUpdate":"2021-06-02"},"enrollment":89,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"interventions":[{"type":"DRUG","name":"SHP465","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SHP465","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.","primaryOutcome":{"measure":"Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale-5 (ADHD-RS-5) Total Score at Week 4","timeFrame":"Baseline, Week 4","effectByArm":[{"arm":"Placebo","deltaMin":-9.7,"sd":null},{"arm":"SHP465","deltaMin":-11.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.451"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":41,"countries":["United States"]},"refs":{"pmids":["33185468"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":43},"commonTop":["Headache"]}}